Role of common mental and physical disorders in partial disability around the world

Background Mental and physical disorders are associated with total disability, but their effects on days with partial disability (i.e. the ability to perform some, but not full-role, functioning in daily life) are not well understood. Aims To estimate individual (i.e. the consequences for an individual with a disorder) and societal effects (i.e. the avoidable partial disability in the society due to disorders) of mental and physical disorders on days with partial disability around the world. Method Respondents from 26 nationally representative samples (n=61 259, age 18+) were interviewed regarding mental and physical disorders, and day-to-day functioning. The Composite International Diagnostic Interview, version 3.0 (CIDI 3.0) was used to assess mental disorders; partial disability (expressed in full day equivalents) was assessed with the World Health Organization Disability Assessment Schedule in the CIDI 3.0. Results Respondents with disorders reported about 1.58 additional disability days per month compared with respondents without disorders. At the individual level, mental disorders (especially post-traumatic stress disorder, depression and bipolar disorder) yielded a higher number of days with disability than physical disorders. At the societal level, the population attributable risk proportion due to physical and mental disorders was 49% and 15% respectively. Conclusions Mental and physical disorders have a considerable impact on partial disability, at both the individual and at the societal level. Physical disorders yielded higher effects on partial disability than mental disorders.

BristolMyers Squibb

Bristol-Myers Squibb

Eli Lilly Company

Eli Lilly Company

GlaxoSmithKline

GlaxoSmithKline

Johnson & Johnson Pharmaceuticals

Johnson & Johnson Pharmaceuticals

OrthoMcNeil Pharmaceuticals

Ortho-McNeil Pharmaceuticals

Pfizer

Pfizer

Sanofi-Aventis

SanofiAventis

US National Institute of Mental Health (NIMH) [R01MH070884]

US National Institute of Mental Health (NIMH)

Mental Health Burden Study

Mental Health Burden Study [HHSN271200700030C]

John D. and Catherine T. MacArthur Foundation

John D. and Catherine T. MacArthur Foundation

Pfizer Foundation

Pfizer Foundation

US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]

US Public Health Service

Fogarty International Center (FIRCA)

Fogarty International Center (FIRCA) [R03-TW006481]

Pan American Health Organization (PAHO)

Pan American Health Organization (PAHO)

Eli Lilly & Company Foundation

Eli Lilly & Company Foundation

OrthoMcNeil Pharmaceutical

Ortho-McNeil Pharmaceutical

Shire

Shire

State of Sao Paulo Research Foundation (FAPESP) [03/00204-3]

State of Sao Paulo Research Foundation (FAPESP)

Ministry of Health

Ministry of Health

National Center for Public Health Protection

National Center for Public Health Protection

Shenzhen Bureau of Health

Shenzhen Bureau of Health

Shenzhen Bureau of Science, Technology, and Information

Shenzhen Bureau of Science, Technology, and Information

Ministry of Social Protection

Ministry of Social Protection

European Commission [QLG5-1999-01042, 2004123]

European Commission

Piedmont Region (Italy)

Piedmont Region (Italy)

Fondo de Investigacion Sanitaria

Fondo de Investigacion Sanitaria

Instituto de Salud Carlos III, Spain [FIS 00/0028]

Instituto de Salud Carlos III, Spain

Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]

Ministerio de Ciencia y Tecnologia, Spain

Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III

Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III [CB06/02/0046, RD06/0011]

Government of India

Government of India

WHO

WHO

Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF)

Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF)

Israel National Institute for Health Policy and Health Services Research

Israel National Institute for Health Policy and Health Services Research

National Insurance Institute of Israel

National Insurance Institute of Israel

Grant for Research on Psychiatric and Neurological Diseases and Mental Health

Grant for Research on Psychiatric and Neurological Diseases and Mental Health [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]

Japan Ministry of Health, Labour and Welfare

Japan Ministry of Health, Labour and Welfare

Lebanese Ministry of Public Health

Lebanese Ministry of Public Health

WHO (Lebanon)

WHO (Lebanon)

Fogarty International

Fogarty International

Janssen Cilag

Janssen-Cilag

Eli Lilly

Eli Lilly

Roche

Roche

Novartis

Novartis

National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES) [4280]

National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES)

National Council on Science and Technology

National Council on Science and Technology [CONACyT-G30544- H]

New Zealand Ministry of Health

New Zealand Ministry of Health

Alcohol Advisory Council

Alcohol Advisory Council

Health Research Council

Health Research Council

WHO (Geneva)

WHO (Geneva)

WHO (Nigeria)

WHO (Nigeria)

Federal Ministry of Health, Abuja, Nigeria

Federal Ministry of Health, Abuja, Nigeria

Health & Social Care Research & Development Division of the Public Health Agency

Health & Social Care Research & Development Division of the Public Health Agency

Champalimaud Foundation

Champalimaud Foundation

Gulbenkian Foundation

Gulbenkian Foundation

Foundation for Science and Technology (FCT)

Foundation for Science and Technology (FCT)

Ministry of Public Health

Ministry of Public Health

US NIMH [R01-MH059575, RO1-MH61905]

US NIMH

National Institute of Drug Abuse (NIDA)

National Institute of Drug Abuse (NIDA)

South African Department of Health

South African Department of Health

University of Michigan

University of Michigan

NIMH

NIMH [U01-MH60220]

Robert Wood Johnson Foundation (RWJF)

Robert Wood Johnson Foundation (RWJF) [044708]